Treatment options have improved

Friedreich’s ataxia is a hereditary neurodegenerative disease that is classically characterized by uncoordinated movements, postural and gait disorders, as well as balance and visual disorders. Subgroups of those affected also suffer from cardiomyopathies, diabetes and scoliosis. Omaveloxolone has recently become available as a new oral treatment option, which has been approved for use by health insurance companies in Switzerland since the beginning of May 2025.